Related Experiment Video

Updated: Feb 26, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K

Atezolizumab for the treatment of non-small cell lung cancer

Fernando C Santini1,2, Charles M Rudin2

  • 1a Division of Medical Oncology , Instituto do Câncer do Estado de São Paulo, Hospital Sírio Libanês , São Paulo , Brazil.

Expert Review of Clinical Pharmacology
|July 18, 2017
PubMed
Abstract

Insights

Atezolizumab, targeting programmed cell death ligand 1 (PD-L1), offers a new treatment for advanced non-small cell lung cancer (NSCLC). While effective, its use in early-stage lung cancer requires further investigation.

Area of Science:

  • Immunology and Oncology
  • Cancer Immunotherapy

Background:

  • The immune system plays a dual role in cancer development and progression.
  • Immune checkpoint inhibitors have transformed cancer treatment, particularly in non-small cell lung cancer (NSCLC).
  • Atezolizumab, a PD-L1 targeting antibody, is a key development in this field.

Purpose of the Study:

  • To provide a drug profile of atezolizumab for NSCLC treatment.
  • To review the cancer-immunity cycle and relevant immunology.
  • To discuss the differences between targeting PD-L1 versus PD-1.

Main Methods:

  • Review of pre-clinical and clinical data for atezolizumab in NSCLC.
  • Discussion of PD-L1 and PD-L2 discovery and their roles.
  • Analysis of challenges associated with PD-L1 immunohistochemistry assays.

Main Results:

  • PD-1:PD-L1 blockade is a cornerstone of modern cancer immunotherapy.
  • Atezolizumab shows promise in treating advanced NSCLC.
  • The efficacy of PD1:PD-L1 blockade in early-stage lung cancer remains under discussion.

Conclusions:

  • Atezolizumab represents a significant advancement in advanced NSCLC treatment.
  • Further research is needed to clarify the role of PD1:PD-L1 blockade in early-stage lung cancer.
  • Understanding PD-L1 expression and assays is crucial for effective immunotherapy.
Keywords:
AtezolizumabPD-L1immunotherapylung cancer

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
508
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.0K